Pulmonary vascular disease & thromboembolismCohort study
Upper Extremity Deep Vein Thrombosis in Cancer Patients
- Prospective registry cohort study
- international
- observational registry
Authors' conclusion
Cancer-associated UEDVT carries higher risks of recurrence and bleeding than noncancer UEDVT. Lung cancer showed the greatest recurrence during treatment. Anticoagulation beyond 90 days was associated with a lower post-treatment recurrence.
Study context
- Population
- Patients with objectively confirmed upper extremity DVT in the RIETE registry2,210 with cancer
- Participants
- 5,195 patients
- Exposure
- Cancer vs no cancer in upper extremity deep vein thrombosis (UEDVT)
- Cancern = 2,210
- Outcome
- Recurrent VTE and bleeding
- Follow-up
- 24 months
Main finding
As reported in the abstract
Cumulative incidence of recurrent VTE and bleeding
| Group | Recurrent venous thromboembolism (VTE) | Bleeding |
|---|---|---|
| Cancer | 3.9% (95% CI: 3.1-4.9) | 6.8% (95% CI: 5.7-8.1) |
| No cancer | 2.5% (95% CI: 1.8-3.5) | 4.3% (95% CI: 3.4-5.3) |
Observational data: associations, not effects.
Further findings
| Outcome | Values | sHR (95% CI) | |
|---|---|---|---|
| Factors associated with recurrence during anticoagulation — Lung cancer vs No cancer | 10.1 (1.31–78.06) | ||
| Factors associated with recurrence during anticoagulation — Age (per year) · younger age associated with recurrence | 0.97 (0.95–0.99) | ||
| Recurrence after anticoagulation discontinuation, by anticoagulation duration — 91 to 180 days vs 30 days or less | 0.49 (0.24–1.00) | ||
| Recurrence after anticoagulation discontinuation, by anticoagulation duration — more than 180 days vs 30 days or less | 0.35 (0.17–0.71) | ||
| 0.050.21520Subdistribution hazard ratio (log scale) |
| Outcome | Values | Estimate |
|---|---|---|
| 24-month recurrence by cancer site (cancer patients) | Lung 6.4% (95% CI 4.0–9.5) · Gastrointestinal 4.0% (95% CI 2.6–6.0) · Genitourinary 3.6% (95% CI 1.6–6.8) · Breast 2.5% (95% CI 1.2–4.5) · Hematologic 1.4% (95% CI 0.5–3.4) |
Safety
| Outcome | sHR (95% CI) | |
|---|---|---|
| Factors associated with bleeding during anticoagulation — Genitourinary cancer vs No cancer | 4.95 (1.16–21.17) | |
| Factors associated with bleeding during anticoagulation — Transient risk factors vs No cancer | 1.75 (1.16–2.64) | |
| 0.050.21520Subdistribution hazard ratio (log scale) |
Original publication
Upper Extremity Deep Vein Thrombosis in Cancer Patients. JACC CardioOncol. doi:10.1016/j.jaccao.2026.05.008
Summarised from the published abstract; every number is checked against it